{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:53Z","timestamp":1792622633500,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40264-025-01628-4","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T18:33:29Z","timestamp":1765478009000},"page":"449-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality Analysis"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-2212","authenticated-orcid":false,"given":"Michele","family":"Fusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"J-L Faillie","year":"2019","unstructured":"Faillie J-L. Case-non-case studies: principle, methods, bias and interpretation. Therapies. 2019;74:225\u201332.","journal-title":"Therapies"},{"key":"1628_CR2","doi-asserted-by":"crossref","unstructured":"Raschi E, Moretti U, Salvo F, Pariente A, Antonazzo IC, Ponti FD, et al. Evolving roles of spontaneous reporting systems to assess and monitor drug safety. Pharmacovigilance [Internet]. 2018 [cited 2019 Feb 3]. https:\/\/www.intechopen.com\/online-first\/evolving-roles-of-spontaneous-reporting-systems-to-assess-and-monitor-drug-safety.","DOI":"10.5772\/intechopen.79986"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","volume":"39","author":"L H\u00e4rmark","year":"2016","unstructured":"H\u00e4rmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39:883\u201390.","journal-title":"Drug Saf"},{"key":"1628_CR4","doi-asserted-by":"crossref","unstructured":"Abraham J. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. In: Tietje C, Brouder A, editors. Handbook of Transnational Economic Governance Regimes [Internet]. Brill | Nijhoff; 2010 [cited 2025 Jan 12]. p. 1041\u201353. https:\/\/brill.com\/view\/book\/edcoll\/9789004181564\/Bej.9789004163300.i-1081_085.xml.","DOI":"10.1163\/ej.9789004163300.i-1081.897"},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40290-024-00549-4","volume":"39","author":"E Scosyrev","year":"2025","unstructured":"Scosyrev E, Behr S, Jain D, Ponnuru A, Michel C. Disproportionality analysis and causal inference in drug safety. Pharm Med. 2025;39:97\u2013107.","journal-title":"Pharm Med"},{"key":"1628_CR6","doi-asserted-by":"publisher","unstructured":"Fusaroli M, Sartori D, van Puijenbroek EP, et al. Charting\nand Sidestepping the Pitfalls of Disproportionality Analysis. Drug Saf (2025). https:\/\/doi.org\/10.1007\/s40264-025-01604-y.","DOI":"10.1007\/s40264-025-01604-y"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40290-022-00429-9","volume":"36","author":"RL Anjum","year":"2022","unstructured":"Anjum RL, Chandler RE, Rocca E. Dispositions and causality assessment in pharmacovigilance: proposing the Dx3 approach for assessing causality with small data sets. Pharm Med. 2022;36:153\u201361.","journal-title":"Pharm Med"},{"key":"1628_CR8","doi-asserted-by":"crossref","unstructured":"B\u00e9gaud B, Judith KJ. Assessing causality from case reports. Textbook of Pharmacoepidemiology. 3rd ed. 2021. p. 246\u201356.","DOI":"10.1002\/9781119701101.ch14"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2165\/00002018-199717060-00004","volume":"17","author":"RHB Meyboom","year":"1997","unstructured":"Meyboom RHB, Hekster YA, Egberts ACG, Gribnau FWJ, Edwards IR. Causal or casual? Drug Saf. 1997;17:374\u201389.","journal-title":"Drug Saf"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Raschi E, Poluzzi E, Hauben M. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin Drug Saf. 2024;23:981\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1044\/2023_JSLHR-22-00739","volume":"66","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Simonsen A, Borrie SA, Low DM, Parola A, Raschi E, et al. Identifying medications underlying communication atypicalities in psychotic and affective disorders: a pharmacovigilance study within the FDA adverse event reporting system. J Speech Lang Hear Res. 2023;66:3242\u201359.","journal-title":"J Speech Lang Hear Res"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jclinepi.2021.06.022","volume":"138","author":"A Mouffak","year":"2021","unstructured":"Mouffak A, Lepelley M, Revol B, Bernardeau C, Salvo F, Pariente A, et al. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. J Clin Epidemiol. 2021;138:73\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1628_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2951","author":"C Khouri","year":"2023","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E. Interpretation of pharmacovigilance disproportionality analyses. Clin Pharmacol Ther. 2023. https:\/\/doi.org\/10.1002\/cpt.2951.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/aje\/kwac137","volume":"191","author":"NA Haber","year":"2022","unstructured":"Haber NA, Wieten SE, Rohrer JM, Arah OA, Tennant PWG, Stuart EA, et al. Causal and associational language in observational health research: a systematic evaluation. Am J Epidemiol. 2022;191:2084\u201397.","journal-title":"Am J Epidemiol"},{"key":"1628_CR15","doi-asserted-by":"publisher","unstructured":"Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski J-L, et al. Are causal statements reported in pharmacovigilance disproportionality analyses using individual case safety reports exaggerated in related citations? A meta-epidemiological study. Drug Saf [Internet]. 2025 [cited 2025 Apr 23]. https:\/\/doi.org\/10.1007\/s40264-025-01524-x.","DOI":"10.1007\/s40264-025-01524-x"},{"key":"1628_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o2588","volume":"379","author":"C Khouri","year":"2022","unstructured":"Khouri C, Fusaroli M, Salvo F, Raschi E. Transparency and robustness of safety signals. BMJ. 2022;379:o2588.","journal-title":"BMJ"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/pds.4128","volume":"26","author":"AC Pacurariu","year":"2017","unstructured":"Pacurariu AC, Coloma PM, Gross-Martirosyan L, Sturkenboom MC, Straus SM. Decision making in drug safety\u2014a literature review of criteria used to prioritize newly detected safety issues. Pharmacoepidemiol Drug Saf. 2017;26:327\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","volume":"32","author":"M Hauben","year":"2009","unstructured":"Hauben M, Aronson JK. Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug-Safety. 2009;32:99\u2013110.","journal-title":"Drug-Safety."},{"key":"1628_CR19","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295\u2013300.","journal-title":"Proc R Soc Med"},{"key":"1628_CR20","doi-asserted-by":"publisher","DOI":"10.4324\/9781003528937-56","volume-title":"When decisions must be based on partial causal knowledge: analyzing causality and evidence for health policy. The Routledge handbook of causality and causal methods","author":"F Andersen","year":"2024","unstructured":"Andersen F, Anjum RL, Rocca E. When decisions must be based on partial causal knowledge: analyzing causality and evidence for health policy. The Routledge handbook of causality and causal methods. Milton Park: Routledge; 2024."},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2105\/AJPH.2018.304337","volume":"108","author":"MA Hern\u00e1n","year":"2018","unstructured":"Hern\u00e1n MA. The c-word: scientific euphemisms do not improve causal inference from observational data. Am J Public Health. 2018;108:616\u20139.","journal-title":"Am J Public Health"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1001\/jama.2024.7741","volume":"331","author":"IJ Dahabreh","year":"2024","unstructured":"Dahabreh IJ, Bibbins-Domingo K. Causal inference about the effects of interventions from observational studies in medical journals. JAMA. 2024;331:1845\u201353.","journal-title":"JAMA"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ije\/dyaa213","volume":"50","author":"PWG Tennant","year":"2021","unstructured":"Tennant PWG, Murray EJ, Arnold KF, Berrie L, Fox MP, Gadd SC, et al. Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations. Int J Epidemiol. 2021;50:620\u201332.","journal-title":"Int J Epidemiol"},{"key":"1628_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/spc3.12948","volume":"18","author":"JM Rohrer","year":"2024","unstructured":"Rohrer JM. Causal inference for psychologists who think that causal inference is not for them. Soc Pers Psychol Compass. 2024;18:e12948.","journal-title":"Soc Pers Psychol Compass"},{"key":"1628_CR25","volume-title":"Inventing temperature: measurement and scientific progress","author":"H Chang","year":"2007","unstructured":"Chang H. Inventing temperature: measurement and scientific progress. Oxford: Oxford University Press; 2007."},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ijnp\/pyac031","volume":"25","author":"M Fusaroli","year":"2022","unstructured":"Fusaroli M, Raschi E, Giunchi V, Menchetti M, Rimondini Giorgini R, De Ponti F, et al. Impulse control disorders by dopamine partial agonists: a pharmacovigilance-pharmacodynamic assessment through the FDA adverse event reporting system. Int J Neuropsychopharmacol. 2022;25:727\u201336.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-022-01258-0","volume":"46","author":"D Sartori","year":"2023","unstructured":"Sartori D, Aronson JK, Nor\u00e9n GN, Onakpoya IJ. Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature. Drug Saf. 2023;46:109\u201320.","journal-title":"Drug Saf"},{"key":"1628_CR28","unstructured":"Gallow JD. The metaphysics of Causation. In: Zalta EN, Nodelman U, editors. The Stanford Encyclopedia of Philosophy [Internet]. Fall 2022. Metaphysics Research Lab, Stanford University; 2022 [cited 2025 Jan 25]. https:\/\/plato.stanford.edu\/archives\/fall2022\/entries\/causation-metaphysics\/."},{"key":"1628_CR29","doi-asserted-by":"publisher","DOI":"10.7551\/mitpress\/10809.001.0001","volume-title":"Actual causality","author":"JY Halpern","year":"2016","unstructured":"Halpern JY. Actual causality. Cambridge: The MIT Press; 2016."},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369.","journal-title":"Stat Methods Med Res"},{"key":"1628_CR31","unstructured":"Fusaroli M, Mitchell J, Rudolph A, Rocca E, Fusaroli R. PVdagger: visualization of causal structures in pharmacovigilance data using DAGs [Internet]. 2025. https:\/\/pvverse.github.io\/pv_dagger\/."},{"key":"1628_CR32","volume-title":"Causal inference: what if","author":"MA Hernan","year":"2024","unstructured":"Hernan MA, Robins JM. Causal inference: what if. Boca Raton: CRC Press; 2024."},{"key":"1628_CR33","first-page":"173","volume":"35","author":"SW Smith","year":"2012","unstructured":"Smith SW, Hauben M, Aronson JK. Paradoxical and bidirectional drug effects. Drug Saf. 2012;35:173\u201389.","journal-title":"Drug Saf"},{"key":"1628_CR34","first-page":"251524592211063","volume":"5","author":"D Deffner","year":"2022","unstructured":"Deffner D, Rohrer JM, McElreath R. A causal framework for cross-cultural generalizability. Adv Methods Pract Psychol Sci. 2022;5:25152459221106370.","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"1628_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/00491241221099552","author":"C Cinelli","year":"2022","unstructured":"Cinelli C, Forney A, Pearl J. A crash course in good and bad controls. Sociol Methods Res. 2022. https:\/\/doi.org\/10.1177\/00491241221099552.","journal-title":"Sociol Methods Res"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1467-9868.2009.00728.x","volume":"72","author":"TJ VanderWeele","year":"2010","unstructured":"VanderWeele TJ, Robins JM. Signed directed acyclic graphs for causal inference. J R Stat Soc Ser B Stat Methodol. 2010;72:111.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/aje\/kwj275","volume":"164","author":"S Hern\u00e1ndez-D\u00edaz","year":"2006","unstructured":"Hern\u00e1ndez-D\u00edaz S, Schisterman EF, Hern\u00e1n MA. The birth weight \u201cparadox\u201d uncovered? Am J Epidemiol. 2006;164:1115\u201320.","journal-title":"Am J Epidemiol"},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/aje\/kwp293","volume":"170","author":"MA Hern\u00e1n","year":"2009","unstructured":"Hern\u00e1n MA, Cole SR. Invited commentary: causal diagrams and measurement bias. Am J Epidemiol. 2009;170:959\u201362.","journal-title":"Am J Epidemiol"},{"key":"1628_CR39","doi-asserted-by":"crossref","unstructured":"Berrie L, Arnold KF, Tomova GD, Gilthorpe MS, Tennant PWG. Depicting deterministic variables within directed acyclic graphs (DAGs): an aid for identifying and interpreting causal effects involving tautological associations, compositional data, and composite variables [Internet]. 2023 [cited 2024 Feb 29]. arXiv:http:\/\/arxiv.org\/abs\/2211.13201.","DOI":"10.1136\/jech-2023-SSMabstracts.111"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/biomet\/ast066","volume":"101","author":"M Kuroki","year":"2014","unstructured":"Kuroki M, Pearl J. Measurement bias and effect restoration in causal inference. Biometrika. 2014;101:423\u201337.","journal-title":"Biometrika"},{"key":"1628_CR41","unstructured":"Finkelstein N, Adams R, Saria S, Shpitser I. Partial identifiability in discrete data with measurement error [Internet]. 2020 [cited 2024 Jun 11]. arXiv:http:\/\/arxiv.org\/abs\/2012.12449"},{"key":"1628_CR42","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/14740338.2021.1933430","volume":"20","author":"M Gahr","year":"2021","unstructured":"Gahr M, Connemann B, Zeiss R, Sch\u00f6nfeldt-Lecuona C, Dreyhaupt J, Lazik C. Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey. Expert Opin Drug Saf. 2021;20:979\u201385.","journal-title":"Expert Opin Drug Saf"},{"key":"1628_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00228-010-0865-7","volume":"66","author":"F van Hunsel","year":"2010","unstructured":"van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66:1143\u201350.","journal-title":"Eur J Clin Pharmacol"},{"key":"1628_CR44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1345\/aph.1M632","volume":"44","author":"FPAM van Hunsel","year":"2010","unstructured":"van Hunsel FPAM, ten Berge EAAM, Borgsteede SD, van Grootheest K. What motivates patients to report an adverse drug reaction? Ann Pharmacother. 2010;44:936\u20137.","journal-title":"Ann Pharmacother"},{"key":"1628_CR45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40264-023-01294-4","volume":"46","author":"K Kralova","year":"2023","unstructured":"Kralova K, Wilson C-A, Richebourg N, D\u2019souza J. Quality of MedDRA\u00ae coding in a sample of COVID-19 vaccine medication error data. Drug Saf. 2023;46:501\u20137.","journal-title":"Drug Saf"},{"key":"1628_CR46","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases the notoriety bias. Drug-Safety. 2007;30:891\u20138.","journal-title":"Drug-Safety."},{"key":"1628_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1473-3099(20)30117-1","volume":"20","author":"L Chouchana","year":"2020","unstructured":"Chouchana L, Pariente A, Pannier E, Tsatsaris V, Treluyer J-M. Dolutegravir and neural tube defects: a new insight. Lancet Infect Dis. 2020;20:405\u20136.","journal-title":"Lancet Infect Dis"},{"key":"1628_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/cpt.879","volume":"103","author":"K Klein","year":"2018","unstructured":"Klein K, Scholl JHG, De Bruin ML, van Puijenbroek EP, Leufkens HGM, Stolk P. When more is less: an exploratory study of the precautionary reporting bias and its impact on safety signal detection. Clin Pharmacol Ther. 2018;103:296\u2013303.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40264-018-0703-x","volume":"42","author":"JR Rogers","year":"2019","unstructured":"Rogers JR, Sarpatwari A, Desai RJ, Bohn JM, Khan NF, Kesselheim AS, et al. Effect of lawyer-submitted reports on signals of disproportional reporting in the Food and Drug Administration\u2019s adverse event reporting system. Drug Saf. 2019;42:85\u201393.","journal-title":"Drug Saf"},{"key":"1628_CR50","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Reich L, DeMicco J, Kim K. Extreme duplication\u201d in the US FDA adverse events reporting system database. Drug Saf. 2007;30:551\u20134.","journal-title":"Drug Saf"},{"key":"1628_CR51","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/pds.5265","volume":"30","author":"M Hauben","year":"2021","unstructured":"Hauben M, Zou C, Bright S, Hung E. More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis. Pharmacoepidemiol Drug Saf. 2021;30:1140\u20131.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","volume":"23","author":"P de Boissieu","year":"2014","unstructured":"de Boissieu P, Kanagaratnam L, Abou Taam M, Roux M-P, Dram\u00e9 M, Trenque T. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2014;23:989\u201392.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR53","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/pds.3474","volume":"22","author":"K Juhlin","year":"2013","unstructured":"Juhlin K, Ye X, Star K, Nor\u00e9n GN. Outlier removal to uncover patterns in adverse drug reaction surveillance\u2014a simple unmasking strategy. Pharmacoepidemiol Drug Saf. 2013;22:1119\u201329.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/pds.4209","volume":"26","author":"M Hauben","year":"2017","unstructured":"Hauben M, Maignen F. Does serious consequential masking exist? An update. Pharmacoepidemiol Drug Saf. 2017;26:727\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR55","doi-asserted-by":"crossref","unstructured":". Adja\u00ef F, Fournier D, Dolladille C, Lebrun-Vignes B, Bihan K. Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case\/non-case analysis. Therapie. 2024;S0040-5957(24)00039-8.","DOI":"10.1016\/j.therap.2024.03.002"},{"key":"1628_CR56","unstructured":"Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). FDA. 2019."},{"key":"1628_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252516","volume":"16","author":"M Wolfschlag","year":"2021","unstructured":"Wolfschlag M, H\u00e5kansson A. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: a nationwide register study in Sweden. PLoS ONE. 2021;16:e0252516.","journal-title":"PLoS ONE"},{"key":"1628_CR58","doi-asserted-by":"publisher","unstructured":"Plummer NR, Tam AW, Mulvaney CA, Preston NJ, Laha SK. Dopamine agonists for traumatic brain injury. Cochrane Database Syst Rev [Internet]. 2018 [cited 2023 Apr 14]. https:\/\/doi.org\/10.1002\/14651858.CD013062\/full.","DOI":"10.1002\/14651858.CD013062\/full"},{"key":"1628_CR59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2021.08.006","volume":"90","author":"M Fusaroli","year":"2021","unstructured":"Fusaroli M, Raschi E, Contin M, Sambati L, Menchetti M, Fioritti A, et al. Impulsive conditions in Parkinson\u2019s disease: a pharmacosurveillance-supported list. Parkinsonism Relat Disord. 2021;90:79\u201383.","journal-title":"Parkinsonism Relat Disord"},{"key":"1628_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41:19\u201375.","journal-title":"Drug Saf"},{"key":"1628_CR61","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40264-023-01329-w","volume":"46","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Salvo F, Bernardeau C, Idris M, Dolladille C, Pariente A, et al. Mapping strategies to assess and increase the validity of published disproportionality signals: a meta-research study. Drug Saf. 2023;46:857\u201366.","journal-title":"Drug Saf"},{"key":"1628_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.668765","volume":"12","author":"C Khouri","year":"2021","unstructured":"Khouri C, Nguyen T, Revol B, Lepelley M, Pariente A, Roustit M, et al. Leveraging the variability of pharmacovigilance disproportionality analyses to improve signal detection performances. Front Pharmacol. 2021;12:668765.","journal-title":"Front Pharmacol"},{"key":"1628_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149144","volume":"11","author":"SB Bruns","year":"2016","unstructured":"Bruns SB, Ioannidis JPA. P-curve and p-hacking in observational research. PLoS ONE. 2016;11:e0149144.","journal-title":"PLoS ONE"},{"key":"1628_CR64","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/JCP.0000000000001881","volume":"44","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Khouri C, Poluzzi E, De Ponti F, Salvo F, Raschi E. Meta-analyzing results from disproportionality analysis of individual case safety reports: a note of caution. J Clin Psychopharmacol. 2024;44:443.","journal-title":"J Clin Psychopharmacol"},{"key":"1628_CR65","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/JCP.0000000000001882","volume":"44","author":"B Williams","year":"2024","unstructured":"Williams B, Lee K, Ewah SO, Neelam K. Response to comments by Dr Fusaroli and colleagues. J Clin Psychopharmacol. 2024;44:445.","journal-title":"J Clin Psychopharmacol"},{"key":"1628_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/JCP.0000000000001773","volume":"44","author":"BD Williams","year":"2024","unstructured":"Williams BD, Lee K, Ewah SO, Neelam K. Aripiprazole and other third-generation antipsychotics as a risk factor for impulse control disorders: a systematic review and meta-analysis. J Clin Psychopharmacol. 2024;44:39\u201348.","journal-title":"J Clin Psychopharmacol"},{"key":"1628_CR67","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40264-023-01353-w","volume":"46","author":"O Gauffin","year":"2023","unstructured":"Gauffin O, Brand JS, Vidlin SH, Sartori D, Asikainen S, Catal\u00e0 M, et al. Supporting pharmacovigilance signal validation and prioritization with analyses of routinely collected health data: lessons learned from an EHDEN network study. Drug Saf. 2023;46:1335\u201352.","journal-title":"Drug Saf"},{"key":"1628_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jole\/lzaa001","volume":"5","author":"SG Roberts","year":"2020","unstructured":"Roberts SG, Killin A, Deb A, Sheard C, Greenhill SJ, Sinnem\u00e4ki K, et al. CHIELD: the causal hypotheses in evolutionary linguistics database. J Lang Evol. 2020;5:101\u201320.","journal-title":"J Lang Evol"},{"key":"1628_CR69","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1075\/pc.22.2.06tyl","volume":"22","author":"K Tyl\u00e9n","year":"2015","unstructured":"Tyl\u00e9n K, Fusaroli R, Bj\u00f8rndahl JS, Raczaszek-Leonardi J, \u00d8stergaard S, Stjernfelt F. Diagrammatic reasoning: abstraction, interaction, and insight. Pragmat Cogn. 2015;22:264\u201383.","journal-title":"Pragmat Cogn"},{"key":"1628_CR70","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s42113-024-00214-8","volume":"7","author":"M Woensdregt","year":"2024","unstructured":"Woensdregt M, Fusaroli R, Rich P, Modr\u00e1k M, Kolokolova A, Wright C, et al. Lessons for theory from scientific domains where evidence is sparse or indirect. Comput Brain Behav. 2024;7:588\u2013607.","journal-title":"Comput Brain Behav."},{"key":"1628_CR71","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s42113-024-00214-8","volume":"7","author":"M Woensdregt","year":"2024","unstructured":"Woensdregt M, Fusaroli R, Rich P, Modr\u00e1k M, Kolokolova A, Wright C, et al. Lessons for theory from scientific domains where evidence is sparse or indirect. Comput Brain Behav. 2024;7:588\u2013607.","journal-title":"Comput Brain Behav"},{"key":"1628_CR72","doi-asserted-by":"publisher","unstructured":"De Pretis F, Landes J, Osimani B. E-Synthesis: a Bayesian framework for causal assessment in pharmacosurveillance. Front Pharmacol [Internet]. 2019 [cited 2024 May 28];10. https:\/\/doi.org\/10.3389\/fphar.2019.01317\/full.","DOI":"10.3389\/fphar.2019.01317\/full"},{"key":"1628_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13194-017-0169-1","volume":"8","author":"J Landes","year":"2018","unstructured":"Landes J, Osimani B, Poellinger R. Epistemology of causal inference in pharmacology. Eur J Philos Sci. 2018;8:3\u201349.","journal-title":"Eur J Philos Sci"},{"key":"1628_CR74","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40264-019-00826-1","volume":"42","author":"E Rocca","year":"2019","unstructured":"Rocca E, Copeland S, Ralph Edwards I. Pharmacovigilance as scientific discovery: an argument for trans-disciplinarity. Drug Saf. 2019;42:1115\u201324.","journal-title":"Drug Saf"},{"key":"1628_CR75","doi-asserted-by":"crossref","unstructured":"Garg P, Fetzer T. Causal claims in economics [Internet]. Rochester: Social Science Research Network; 2024 [cited 2025 Jan 10]. https:\/\/papers.ssrn.com\/abstract=5009061.","DOI":"10.2139\/ssrn.5045487"},{"key":"1628_CR76","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jech-2022-219267","volume":"76","author":"E Igelstr\u00f6m","year":"2022","unstructured":"Igelstr\u00f6m E, Craig P, Lewsey J, Lynch J, Pearce A, Katikireddi SV. Causal inference and effect estimation using observational data. J Epidemiol Community Health. 2022;76:960\u20136.","journal-title":"J Epidemiol Community Health"},{"key":"1628_CR77","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12874-021-01426-3","volume":"21","author":"JJM Rijnhart","year":"2021","unstructured":"Rijnhart JJM, Lamp SJ, Valente MJ, MacKinnon DP, Twisk JWR, Heymans MW. Mediation analysis methods used in observational research: a scoping review and recommendations. BMC Med Res Methodol. 2021;21:226.","journal-title":"BMC Med Res Methodol"},{"key":"1628_CR78","doi-asserted-by":"crossref","first-page":"A43","DOI":"10.1136\/jech-2014-204323","volume":"71","author":"PWG Tennant","year":"2017","unstructured":"Tennant PWG, Textor J, Gilthorpe MS, Ellison GTH. OP87 dagitty and directed acyclic graphs in observational research: a critical review. J Epidemiol Community Health. 2017;71:A43\u2013A43.","journal-title":"J Epidemiol Community Health"},{"key":"1628_CR79","volume":"6","author":"ZJ Kunicki","year":"2023","unstructured":"Kunicki ZJ, Smith ML, Murray EJ. A primer on structural equation model diagrams and directed acyclic graphs: when and how to use each in psychological and epidemiological research. Adv Methods Pract Psychol Sci. 2023;6:25152459231156085.","journal-title":"Adv Methods Pract Psychol Sci"},{"key":"1628_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-00955-4","volume":"9","author":"E Tay","year":"2024","unstructured":"Tay E, Dymock M, Lopez L, Glover C, Huang YA, Bakar KS, et al. Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study. npj Vaccines. 2024;9:1\u20138.","journal-title":"npj Vaccines."},{"key":"1628_CR81","unstructured":"Murray EJ, Kunicki Z. As the wheel turns: causal inference for feedback loops and bidirectional effects. 2024 [cited 2024 Feb 14]. https:\/\/osf.io\/9em5q."},{"key":"1628_CR82","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pds.5610","volume":"32","author":"MDX van der Boom","year":"2023","unstructured":"van der Boom MDX, van Eekeren R, van Hunsel FPAM. Observed-over-expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting. Pharmacoepidemiol Drug Saf. 2023;32:783\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1628_CR83","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40264-024-01448-y","volume":"47","author":"C Zaccaria","year":"2024","unstructured":"Zaccaria C, Piccolo L, Gordillo-Mara\u00f1\u00f3n M, Touraille G, de Vries C. Identification of pregnancy adverse drug reactions in pharmacovigilance reporting systems: a novel algorithm developed in EudraVigilance. Drug Saf. 2024;47:1127\u201336.","journal-title":"Drug Saf"},{"key":"1628_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01559-0","author":"L Sandberg","year":"2025","unstructured":"Sandberg L, Vidlin SH, K-P\u00e1pai L, Savage R, Raemaekers BC, Taavola-Gustafsson H, et al. Uncovering pregnancy exposures in pharmacovigilance case report databases: a comprehensive evaluation of the VigiBase pregnancy algorithm. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01559-0.","journal-title":"Drug Saf"},{"key":"1628_CR85","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241228119","volume":"15","author":"A Lomeli-Silva","year":"2024","unstructured":"Lomeli-Silva A, Contreras-Salinas H, Barajas-Virgen MY, Romero-Lopez MS, Rodr\u00edguez-Herrera LY. Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation. Ther Adv Drug Saf. 2024;15:20420986241228119.","journal-title":"Ther Adv Drug Saf"},{"key":"1628_CR86","unstructured":"Pan American Health Organization. System for evaluation of the National Regulatory Authorities for medicines [Internet]. 2018. https:\/\/www3.paho.org\/hq\/index.php?option=com_content&view=article &id=1615:2009-sistema-evaluacion-autoridadesreguladoras-nacionales-medicamentos&Itemid =1179&lang=en#gsc.tab=0."},{"key":"1628_CR87","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47:585\u201399.","journal-title":"Drug Saf"},{"key":"1628_CR88","unstructured":"Hern\u00e1n M, Robins J. Causal inference: what if [Internet]. Boca Raton: Chapman & Hall\/CRC; 2020 [cited 2025 Apr 28]. https:\/\/miguelhernan.org\/whatifbook."},{"key":"1628_CR89","unstructured":"Huntington-Klein N. The effect: an introduction to research design and causality [Internet]. CRC Press. Taylor and Francis Group; 2023 [cited 2025 Apr 28]. https:\/\/theeffectbook.net\/."},{"key":"1628_CR90","unstructured":"Pearl J. Causality [Internet]. 2nd ed. Cambridge: Cambridge University Press; 2009 [cited 2025 May 3]. https:\/\/www.cambridge.org\/core\/books\/causality\/B0046844FAE10CBF274D4ACBDAEB5F5B."},{"key":"1628_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ectj\/utad008","volume":"28","author":"P H\u00fcnermund","year":"2025","unstructured":"H\u00fcnermund P, Bareinboim E. Causal inference and data fusion in econometrics. Econom J. 2025;28:41\u201382.","journal-title":"Econom J"},{"key":"1628_CR92","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01628-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:01:11Z","timestamp":1773939671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01628-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable because spontaneous reports of FAERS are anonymous and publicly available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because spontaneous reports of FAERS are anonymous and publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publication"}},{"value":"The data that support the findings of this study are publicly available in their raw form at\n                      \n                      , and in their clean version through DiAna. An open-access toolkit for DIsproportionality ANAlysis and other pharmacovigilance investigations in FAERS (\n                      \n                      ).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The script, using functions from the DiAna and PVdagger R packages, is made available as supplementary material, and as a tutorial at the website of the DiAna package (\n                      \n                      ).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Script availability statement"}},{"value":"MF, RF conceptualised and designed the study. The formal analyses and visualisation were performed by MF. MF, RF wrote the original draft. MF, JM, AR, ER, RF strongly contributed to the systematisation of the framework, and to the review and editing of the draft. MF, JM, AR, ER, RF read and approved the final version. MF was the creator of the related Pvdagger R package.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"We followed the checklist from the READUS-PV guidelines [\n                      \n                      ,\n                      \n                      ] as much as applicable, taking into account that this is a methodological study, using several drug-event combinations as examples.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Adherence to reporting guidelines"}}]}}